Editorial & Medical Review Policy
CBD is a confusing thing to shop for. The market is barely regulated, the claims are often wild, and it can be hard to tell who is actually being straight with you. That is the gap we try to fill. This page is a plain account of how CBD Nerds works: who writes our content, how we research and review it, the standards we hold ourselves to, and what we do when we get something wrong.
How we source information
We start with peer-reviewed research. For health and science content, that means studies published in journals such as Cannabis and Cannabinoid Research, Neuropsychopharmacology, The Journal of Pain, and Frontiers in Neurology, among others. We also draw on established government health bodies including the FDA, NIH, National Cancer Institute, and CDC, and on guidance from professional medical organizations where relevant.
Research is not all equal
We use an evidence hierarchy when deciding how much weight to give a finding. Systematic reviews and meta-analyses, which pool and synthesize data from multiple independent studies, sit at the top. Below that, we prioritize human clinical trials and randomized controlled trials, then observational studies in humans, then animal research, and finally laboratory or in vitro findings. Where the evidence for a particular use is early-stage or limited to preclinical research, we say so. We do not present animal or laboratory findings as proof of effectiveness in people.
Brand-funded studies
When a study has been funded by a manufacturer or a brand with a financial interest in the outcome, we factor that potential conflict into how we evaluate the findings. We do not automatically dismiss industry-funded research, but we weigh it alongside independent studies and note the funding source where it is material.
Certificates of Analysis (COAs)
For product content, our writers check the COA supplied by the brand or publicly available through the testing laboratory. We assess COAs for cannabinoid potency, residual solvents, pesticides, heavy metals, and microbial contaminants. Where a COA raises questions or appears inconsistent with product claims, we note those concerns. Our guide to reading CBD lab tests explains the evaluation process in detail.
Health claims are supported by referenced sources, linked inline where possible. We prioritize primary sources over secondary reporting. Citation formatting may vary across articles; where peer-reviewed studies are cited, we include enough detail for readers to locate the original source.
Our writers
Every article on CBD Nerds carries a named byline. Our writers are not anonymous, and their background is relevant to what they cover. Their job is to communicate evidence accurately, not to give medical advice, and they are distinct from the scientific and medical reviewers described in the next section.
- Gleb Oleinik covers CBD product roundups and educational content. He is a freelance health writer based in Vancouver, Canada, with extensive experience in CBD and cannabinoid research.
- Calvin Chan, Ph.D. covers health conditions and educational content. He is a researcher and medical writer based in Edmonton, Canada, and holds a PhD from the University of Alberta.
- Paul James covers CBD guides, legality content, and THC product pages. He is a content manager and long-time CBD writer who specializes in turning complex cannabinoid, dosage, and legal topics into plain, practical guidance.
- Kit O’Connell is a journalist and content creator based in Austin, Texas. He served as Editor in Chief of Ministry of Hemp from 2017 to 2021, with additional bylines in HEMP Magazine, Truthout, and the Texas Observer. He handles brand reviews and editorial content.
- Olivia Walters covers product roundups, health conditions content, and pet CBD, and brings a first-hand user perspective to the products she reviews.
- Zack Ruskin covers news and regulatory content. He is a freelance reporter based in San Francisco with bylines in Vanity Fair, Rolling Stone, Leafly, and the San Francisco Chronicle.
Medical & scientific review
Health-related content on CBD Nerds, including articles on specific medical conditions, CBD side effects, drug interactions, and dosage guidance, goes through review by a qualified member of our Scientific Advisory team before publication.
Scientific review and medical review serve different purposes
Scientific review is conducted by researchers with advanced degrees in relevant fields. It focuses on evidence quality: whether health claims align with available research, whether citations accurately represent what studies found, and whether study limitations are properly acknowledged. Medical review draws on clinical healthcare expertise to assess safety information, drug interaction risks, and whether content aligns with current medical practice. Which type a piece of content needs depends on its subject matter and the nature of its health claims.
What reviewers check
Regardless of review type, reviewers assess whether claims are consistent with the available evidence, whether citations are accurately described, whether safety considerations are adequately covered, and whether any language overstates preliminary findings or implies clinical effectiveness that has not been established.
What review is not
Review confirms that content accurately represents available evidence. It does not constitute medical advice and does not establish any kind of clinical relationship between the reviewer and the reader. Our reviewers have no financial stake in the products or brands covered on the site, and they take no part in our commercial or affiliate decisions.
Reviewed articles display the reviewer’s name and credentials in the byline section. If a piece has not been reviewed by an advisory team member, it will not indicate otherwise.
- Nathan Navidzadeh, M.Sc. holds a Master’s degree in Biology from McGill University and serves as a scientific reviewer. He covers mental health content including anxiety, PTSD, depression, and sleep, as well as general cannabinoid science topics. Check Nathan Navidzadeh on LinkedIn
- Ana Luiza Dias, Ph.D. is a biologist with a Ph.D. in Psychobiology (Sleep Science) and a specialist in Biotechnology. She reviews content in the mental health cluster as a scientific reviewer, with a focus on conditions where the research is still developing. Look for Ana Luiza Dias on LinkedIn
- Ashwini Kulkarni holds a Doctor of Science in Microbiology and a diploma in the sustainable management of natural resources. She reviews content related to inflammation, immunity, and physical health conditions. Look for Dr. Ashwini Kulkarni on LinkedIn
Who reviews what
Different content types go through different review processes:
| Content Type |
Writer |
Review Process |
| Health conditions |
Calvin Chan, Ph.D.; Olivia Walters |
Scientific Advisory sign-off required |
| CBD education and guides |
Paul James; Gleb Oleinik |
Scientific Advisory for health-adjacent topics |
| Legality and CBD news |
Paul James; Zack Ruskin |
Editorial fact-check |
| Product roundups |
Gleb Oleinik; Kit O'Connell; Olivia Walters |
Named tester attribution |
| Condition-specific product roundups |
Gleb Oleinik; Kit O'Connell; Olivia Walters |
Scientific Advisory review when the roundup contains specific health claims |
| CBD reviews |
Kit O'Connell with named tester |
Second named editorial reviewer |
| THC products |
Gleb Oleinik; Paul James |
Scientific Advisory review for safety content |
| Pet CBD content |
Olivia Walters |
Editorial review; specialist veterinary review not currently in place |
Editorial independence & commercial relationships
CBD Nerds earns affiliate commission on purchases made through links on the site. The affiliate disclosure in the site footer explains this relationship, and affiliate revenue funds the site.
Affiliate commission rates do not determine which products appear in our roundups, which products rank higher, or what scores products receive. Products are assessed on their merits: potency, COA quality, formulation, value, and tester experience where available. A product we affiliate with can be rated poorly or removed from a list if quality changes. A product we do not affiliate with can appear if it is the right recommendation for the reader.
When a brand provides a product for review, that is disclosed in the article. Brands do not pay for placement in our content, and commercial relationships do not influence editorial assessments. If sponsored content were ever to appear, it would be clearly labelled as such and not presented as independent editorial. We do not currently publish sponsored articles.
How we test products
Firsthand testing is a priority. When a product has been tested, we document who tested it, where they are based, the format and strength used, and when. When we have not tested something ourselves, we say so, and we never fabricate testing, personal experiences, or user feedback.
Where we draw on verified customer feedback from places like Reddit, Trustpilot, and retailer review sections, we present it as external user experience, not as our own first-hand assessment. The full method, including how we score products, handle brand-supplied samples, and assess products we have not used directly, lives on our Our Process page.
Health claims & scientific evidence
CBD research is active but uneven. Some areas have more robust human clinical evidence than others, and we aim to reflect that honestly.
We do not claim that CBD products can diagnose, treat, prevent, or cure medical conditions. It is worth being precise about what FDA approval looks like for cannabinoid medicines. Epidiolex is the only FDA-approved prescription medication made from purified plant-derived CBD, indicated for specific rare forms of epilepsy including Lennox-Gastaut syndrome and Dravet syndrome. The FDA has also approved synthetic cannabinoid medicines for other clinical uses, including dronabinol (sold as Marinol and Syndros) for chemotherapy-related nausea and HIV/AIDS-related appetite loss, and nabilone (Cesamet) for chemotherapy-related nausea. These are prescription drugs with specific medical approvals. Retail hemp-derived CBD products are not FDA-approved treatments for any medical condition, and we do not describe them as such.
When we write about CBD’s potential role in conditions like anxiety, sleep, or pain, we describe what current research suggests, distinguish early-stage findings from established evidence, and note where human clinical data is limited. “Research shows some early promise for sleep” is an accurate characterization of many areas of CBD science. “CBD treats insomnia” is not, and you will not find that language here.
Potential downsides are covered alongside potential benefits: side effects, drug interactions, and the limitations of available studies. If a product category carries safety considerations, those are addressed directly.
THC and age restrictions
We cover hemp-derived THC products, such as Delta-8 and Delta-9, for a 21+ audience only, and we lead with legality. The law varies from state to state and changes often, so we flag the current state-by-state picture where we can and remind readers to check their own local rules before buying. THC content also carries safety guidance on dosing, impairment, and not mixing with alcohol or driving.
Corrections & update policy
Reporting and correcting errors
If you believe something on CBD Nerds is factually incorrect, use the contact page to flag the specific claim, the article where it appears, and the source you believe contradicts it. The editorial team will review the report and decide whether a correction is needed.
We distinguish between minor editorial edits, such as phrasing, broken links, or formatting, and substantive factual corrections where a claim that could affect a reader’s understanding or decision-making was wrong. Minor edits are made as needed. Significant factual corrections are documented in the article with a dated note describing what changed and why. We do not silently rewrite content to remove errors; if a material fact was wrong, that correction is acknowledged.
Content updates
CBD science, cannabis regulation, and product markets change. New research is published, FDA guidance evolves, and state laws shift. When these changes affect the accuracy of an existing article, we update accordingly. Each article displays the original publication date and the date of its most recent significant update, and if an article has been reviewed by a Scientific Advisory team member after publication, the review date is noted separately.
Updates are triggered by material changes: new clinical findings, shifts in regulatory status, significant changes in scientific consensus, or guidance from health bodies. Articles are reassessed when there is a substantive reason to do so, not on an arbitrary timetable. Health content that has been substantially updated may require additional scientific review before republishing.
Product review updates
Product reviews are revisited when there is reason to believe the content no longer accurately reflects the product. Triggers include a confirmed formula change, new COA results that differ materially from previous testing, significant pricing or availability changes, or credible and consistent reader feedback pointing to a change in quality. Review verdicts are tied to the product at the time of testing, and the testing date appears in every review so readers can judge current relevance.
Questions about this policy
Questions about how a specific article was produced, reviewed, or updated can be directed to the contact page.
For more on our team, our testing process, and how the site operates, visit our About Us page.